New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > Central Nervous System

Central Nervous System Regimens



Glioblastoma Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
CNS GBM - temozolomide chemoradiation followed by temozolomide
components ▾
263911000210102
2.0.0
04/07/2023
Part 1: temozolomide chemoradiation
263921000210107
0.0.4
Part 2: temozolomide following chemoradiation
263931000210109
0.0.7
CNS GBM Adjuvant - lomustine and temozolomide chemoradiation
506451000210107
1.0.0
23/05/2025
CNS GBM Recurrent - beVACizumab and irinotecan 125 mg/m2
264261000210107
2.0.0
23/05/2023
CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2
264371000210105
1.0.0
23/05/2023
CNS GBM Recurrent - beVACizumab and lomustine
263971000210106
1.0.0
28/03/2023
CNS GBM Recurrent - beVACizumab Q2W
263961000210100
1.0.0
28/03/2023
CNS GBM Recurrent - beVACizumab Q3W
263951000210103
1.0.0
28/03/2023
CNS GBM Recurrent - lomustine
264281000210104
1.0.0
25/04/2023

Glioma Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [high grade]
264251000210109
2.0.0
13/08/2023
CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [low grade]
264241000210106
2.0.0
13/08/2023
CNS GLI Recurrent - temozolomide [continuous dose-intense] [high grade]
264271000210101
2.0.0
13/08/2023
CNS GLI Recurrent - temozolomide [high grade]
263941000210101
2.0.0
13/08/2023